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Low density lipoprotein receptor-related protein (LRP) belongs to the low-density
lipoprotein receptor family, generally recognized as cell surface endocytic receptors, which
bind and internalize extracellular ligands for degradation in lysosomes. Neurons require
cholesterol to function and keep the membrane rafts stable. Cholesterol uptake into the
neuron is carried out by ApoE via LRPs receptors on the cell surface. In neurons the
most important are LRP-1 and LRP-2, even it is thought that a causal factor in Alzheimer’s
disease (AD) is the malfunction of this process which cause impairment intracellular
signaling as well as storage and/or release of nutrients and toxic compounds. Both
receptors are multifunctional cell surface receptors that are widely expressed in several
tissues including neurons and astrocytes. LRPs are constituted by an intracellular (ICD)
and extracellular domain (ECD). Through its ECD, LRPs bind at least 40 different ligands
ranging from lipoprotein and protease inhibitor complex to growth factors and extracellular
matrix proteins. These receptors has also been shown to interact with scaffolding and
signaling proteins via its ICD in a phosphorylation-dependent manner and to function as
a co-receptor partnering with other cell surface or integral membrane proteins. Thus,
LRPs are implicated in two major physiological processes: endocytosis and regulation
of signaling pathways, which are both involved in diverse biological roles including
lipid metabolism, cell growth processes, degradation of proteases, and tissue invasion.
Interestingly, LRPs were also localized in neurons in different stages, suggesting that
both receptors could be implicated in signal transduction during embryonic development,
neuronal outgrowth or in the pathogenesis of AD.
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THE LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) FAMILY
The LDLR family consists of more than 11 receptors that function
in receptor-mediated endocytosis and cellular signaling (Herz and
Bock, 2002). In addition to the LDLR itself, the family includes
LRP1 (Herz et al., 1988), LRP-2, also called megalin, (Spuch and
Navarro, 2010a,b), VLDLR (Takakashi et al., 1992), LRP5 (Hey
et al., 1998; Kim et al., 1998), LRP6 (Brown et al., 1998), ApoE
receptor 2 (ApoER2), also called LRP8 (Kim et al., 1996; Novak
et al., 1996; Brandes et al., 1997), sorLA-1, also called LR11,
(Jakobsen et al., 1996; Yamazaki et al., 1996), LRP1B (Liu et al.,
2000) and the most recently identified the LRAD3 (Ranganathan
et al., 2011). A model depicting the major structural components
of the representative receptors is shown in Figure 1.
LOW DENSITY LIPOPROTEIN RECEPTOR-RELATEDPROTEIN-1 (LRP1)
The LRP1, also known as CD91 or α2macroglobulin receptor, is
a multifunctional scavenger and signaling receptor that belongs
to the LRP family (Bruno et al., 2010; Boucher and Herz, 2011).
LRP1 is a massive protein (600 kDa) that is proteolytically nicked
during biosynthesis to give two stably associated polypeptides:
an 85-kDa membrane-spanning C-terminal fragment and a
515-kDa extracellular N-terminal chain. The extracellular heavy
α-chain of LRP1 is non-covalently coupled to the transmembrane
and cytoplasmic light β-chain domain. The α-chain contains
four ligand-binding domains (clusters 1–4), consisting of 2, 8,
10, and 11 cysteine-rich complement-type repeats, respectively
(Obermoeller-McCormick et al., 2001) (Figure 1). The LRP1
ligand-binding domains 2 and 4 are the major LRP1 binding
regions interacting with a diverse array of approximately forty
structurally diverse ligands. LRP1 is expressed abundantly on
neurons (Moestrup and Verroust, 2001; Kanekiyo et al., 2011),
where its fundamental role is the uptake of cholesterol and fatty
acids required for synapse formation (Mauch et al., 2001; Fester
et al., 2009). In addition, LRP1 binds more than 30 ligands extra-
cellularly, including ApoE, α2-macroglobulin, tissue plasminogen
activator (tPA), proteinase-inhibitors, blood coagulation factors,
receptor-associated protein (RAP), Aβ, prion protein and apro-
tinin (Hussain et al., 1999; Neels et al., 1999; Herz, 2001; Herz
and Strickland, 2001; Croy et al., 2003; Deane et al., 2004a,b;
Meijer et al., 2007; Demeule et al., 2008; Lillis et al., 2008; Parkyn
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FIGURE 1 | Schematic domain organization of LRP1. The LRP1 contains
five different domains: (A) the ligand-binding domain, (B) the EGF-precursor
homology domain, (C) the O-linked sugar domain, (D) the transmembrane
domain and (E) the intracellular domain. The ligand-binding domain consists
of four clusters and mediates the binding to ligands (see Table 1). The
hydrophobic transmembrane domain ensures the anchoring the LRP1 in the
plasma membrane. The cytoplasmic tail of the LRP1 containing the
characteristic NPXY sequence interact with phospho-tyrosine binding
domains of cellular adaptors proteins which are important for endocytosis and
subsequent intracellular transport. The LRP1 is proteolytically cleaved within
the Golgi complex to generate two subunits: (A) the N-terminal 515-kDa
α-subunit containing the ligand-binding domains and (B) the C-terminal
85-kDa β-subunit containing an extracellular part, the transmembrane
spanning domain and the cytoplasmic intracellular domain. The cytoplasmatic
LRP1 α-subunit contains diverse potential endocytosis and signaling motifs:
two NPXY motifs whereas the distal NPXY sequence overlaps with the
endocytosis signal XYYL and two dileucine motifs. With arrows is indicating
the cleavage events in the molecule and the resulting fragments.
et al., 2008) (Table 1). Interestingly, its cytoplasmic domain binds
to endocytic and scaffold adaptors that link the receptor to other
membrane proteins, including Amyloid Precursor Protein (APP)
(Herz and Chen, 2006; Waldron et al., 2008). The cytoplasmic
tail of LRP1 contains two NPXY motifs, one YXXL motif and
two di-leucine motifs (Li et al., 2001). It has been suggested that
these motifs may be associated with the rapid endocytotic rate of
LRP1 (Deane et al., 2008). The cytoplasmic tail is phosphorylated
on serine and/or tyrosine residues (van der Geer, 2002) and
can interact with different adaptor proteins associated with cell
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Table 1 | Ligands of LRP1 and LRP2.
Receptor Ligands References
LRP1 and LRP2 Albumin Cui et al., 1996
LRP2 Aminoglycosides Moestrup and Verroust,
2001
LRP2 α-Amilase Birn et al., 2000
LRP1 and LRP2 Angiotensin II Gonzalez-Villalobos et al.,
2005
LRP1 and LRP2 Angiotensin 1–7 Gonzalez-Villalobos et al.,
2006
LRP1 and LRP2 ApoB Stefansson et al., 1995
LRP1 and LRP2 ApoE Willnow, 1999
LRP1 and LRP2 ApoH Moestrup and Verroust,
2001
LRP1 and LRP2 Apoj (Clusterin) Kounnas et al., 1995;
Hammad et al., 1997
LRP1 and LRP2 ApoM Faber et al., 2006
LRP1 and LRP2 Aprotinin Moestrup and Verroust,
2001
LRP1 and LRP2 Bone morphogenetic
protein 4 Spoelgen et al., 2005
LRP1 and LRP2 Ca2+ Christensen and Nielsen,
2007
LRP1 and LRP2 Cathepsin b Nielsen et al., 2007
LRP1 and LRP2 Coagulation Factor VIII Ananyeva et al., 2008
LRP1 and LRP2 Connective tissue
growth factor
Gerritsen et al., 2010;
Kawata et al., 2012
LRP1 and LRP2 Cytochrome C Lee et al., 2012
LRP1 and LRP2 Cystatin C Kaseda et al., 2007
LRP1 and LRP2 Epidermal growth factor Orlando et al., 1998
LRP1 and LRP2 Folate binding protein Birn et al., 2005
LRP1 Frizzled-1 Zilberberg et al., 2004
LRP2 α-galactosidase Christensen and Nielsen,
2007
LRP2 Gelsolin Vargas et al., 2010a
LRP1 and LRP2 Hemoglobin Gburek et al., 2002
LRP1 and LRP2 Insulin Orlando et al., 1998
LRP2 Insulin Growth factor I Carro et al., 2002
LRP1 and LRP2 Lactoferrin Willnow, 1999
LRP1 and LRP2 Leptin Dietrich et al., 2008
LRP1 and LRP2 Lipoprotein lipase Knauer et al., 1993
LRP2 Liver type fatty acid
binding protein
Oyama et al., 2005
LRP2 Lysozyme Orlando et al., 1998
LRP1 and LRP2 Metallothionein Klassen et al., 2004
LRP2 Microglobulin Leheste et al., 1999
LRP2 Myoglobulin Gburek et al., 2002
LRP2 Neutrophil gelatinase
associated lipocalin
Hvidberg et al., 2005
LRP2 Odorant binding protein Leheste et al., 1999
LRP2 Parathyroid hormone Hilpert et al., 1999
LRP2 Pancreatitis associated
protein 1
Leheste et al., 1999
LRP1 and LRP2 Plasminogen Kanalas and Makker, 1993
(Continued)
Table 1 | Contined
Receptor Ligands References
LRP1 and LRP2 Plasminogen activator
inhibitory type 1
Stefansson et al., 1995
LRP1 and LRP2 Plasminogen activator
inhibitory type 1
urokinase
Moestrup and Verroust,
2001
LRP1 and LRP2 Plasminogen activator
inhibitory type 1 tissue
plasminoegen activator
Kanalas and Hopfer,
1997; Moestrup and
Verroust, 2001
LRP2 Polymyxin B Moestrup and Verroust,
2001
LRP2 Prolactin Orlando et al., 1998
LRP2 Pro Urokinase Stefansson et al., 1995
LRP1 and LRP2 Retinol binding protein Christensen and Nielsen,
2007
LRP2 Seleno protein P Olson et al., 2008
LRP2 Seminal vesicle
secretory protein II
Ranganathan et al., 1999
LRP2 Sex hormone binding
globulin
Hammes et al., 2005
LRP1 and LRP2 Sonic hedgehog protein Christ et al., 2012
LRP2 Thyroglobulin Zheng et al., 1998
LRP2 Transcobalamin vitamin
B12
Moestrup and Verroust,
2001
LRP2 Transthyretin Sousa et al., 2000
LRP2 Trichosantin Chan et al., 2000
LRP2 Vitamin D binding protein Nykjaer et al., 1999
signaling, such as disabled-1 (Dab1), FE65 (Klug et al., 2011)
and postsynaptic density protein 95 (PSD95) (Trommsdorff et al.,
1998; Gotthardt et al., 2000; Herz et al., 2009). Thus, LRP1 has
a dual role as a receptor which internalizes its ligands acting
like a rapid cargo endocytotic cellular transporter and also as
transmembrane cell signaling receptor (Pflanzner et al., 2011).
LRP1 expression in the brain
LRP1 is highly expressed in neurons (Andersen and Willnow,
2006), mainly of the entorhinal cortex, hippocampus and cere-
bellum, activated astrocytes (Rebeck et al., 1995), and microglia
(Marzolo et al., 2000). Importantly, LRP1 is further expressed in
the central nervous system in different cell types within the neu-
rovascular unit including vascular cells such as brain endothelial
cells, vascular smooth muscle cells and pericytes, and it is also
expressed in the choroid plexus of the blood-brain barrier (BBB)
(Herz and Bock, 2002).
LRP1 and signal transduction in the brain
In neurons LRP1 ismainly implicated promoting local catabolism
of Aβ. LRP1 is found in the somatodendritic compartment of
neurons (Brown et al., 1997), and it can mediate the endocyto-
sis of extracellular ligands in these cells (Makarova et al., 2003).
LRP1 also interacts with the neuronally expressed APP (Knauer
et al., 1996; Kinoshita et al., 2001) and regulates its proteolytical
processing as well as the production of the Aβ peptide (Pietrzik
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et al., 2002), a process that is of central importance for the
pathogenesis of AD. Direct binding of LRP1 to the APP has been
shown to affect endoproteolytic processing of APP to increase
the production of Aβ42 peptides (Rebeck et al., 2001), which
are the major constituent of amyloid plaques (Iwatsubo et al.,
1994). LRP1 can promote Aβ production by altering the process-
ing of APP through interactions via the Kunitz protease inhibitor
(KPI) domain. Although the non-KPI-APP isoform can weakly
bind to LRP1 through cytoplasmic adaptor proteins, such as FE65
(Pietrzik et al., 2004), APP695 processing may not be significantly
influenced by LRP1. Rather than promoting local catabolism of
Aβ in neurons, LRP1, which is expressed in the neurovascular unit
and the choroid plexus might alsomediate export of Aβ across the
BBB and brain cerebrospinal fluid barrier (BCSFB) (Deane et al.,
2004a,b; Zlokovic, 2004). In brain endothelial cells and epithe-
lial cells of the choroid plexus LRP1 may bind directly to Aβ1-40
and export it across the BBB and BCSFB (Deane et al., 2004a,b;
Fujiyoshi et al., 2011). In this context, LRP1 and P-glycoprotein
(P-gp) have been implicated in Aβ efflux (Shibata et al., 2000;
Hartz et al., 2010; Katsouri and Georgopoulos, 2011). LRP-1 is
located on the abluminal endothelial cell membrane, whereas
P-gp is located on the luminal (blood-facing) surface. The recep-
tor for advanced glycation end products (RAGE), also located on
the luminal side of the endothelium, has been linked to Aβ influx
(Deane et al., 2003; Sagare et al., 2011a,b).
LRP-1 is also playing other important roles in the central
nervous system (Fuentealba et al., 2009, 2010), especially in neu-
rons where it is highly expressed and where it interacts with
numerous neuronal proteins such as the postsynaptic density
protein 95 (PSD-95) and the N-methyl-D-Aspartate (NMDA)
receptor. LRP1 has been found to regulate calcium influx into
neurons following stimulation with the glutamate receptor ago-
nist NMDA (Qiu et al., 2002). The molecular mechanism that
underlies this effect has not yet been identified. However, the
possibility that LRP1 might modulate the functions of neuronal
synaptic proteins is in agreement with the results by May et al.
(2002); using primary cultured neurons, they showed that LRP1
is present in close proximity to the NMDA receptor in dendritic
synapses and can be co precipitated with both NMDA receptor
subunits and the postsynaptic density protein PSD-95. Moreover,
treatment with NMDA, but not dopamine, reduces the inter-
action of LRP1 with PSD-95, indicating that LRP1 participates
in transmitter-dependent postsynaptic responses, where it would
be able to modulate the conductance of neuronal ion channels.
Moreover, LRP1 has been shown to regulate calcium signaling
in vitro (Bacskai et al., 2000), an important second messenger
during glutamate neurotransmission. The active form of α2M, an
LRP2 ligand, inhibits the calcium-dependent NMDA responses
and the expression of NMDA receptors, through a signaling path-
way involving LRP1 (Qiu et al., 2002). In fact, mice lacking LRP1
in neurons exhibit a severe mobility disorder, hyperactivity and
premature death (May et al., 2004)
An interesting function of LRP1 in neurons is its ability
to bind prion protein (PrP) in neurons. Several papers argue
that LRP1 controls the surface and biosynthetic trafficking of
normal cellular prion protein (PrPC) in neurons. The traffick-
ing of PrPC is believed to control its conversion to the altered
conformation (designated PrPSc) associated with prion disease.
It was demonstrated that LRP1 is able to associates with PrPC
during its endocytosis and is functionally required for this pro-
cess. Experimentally it was showed that PrPC and LRP1 can be
co-immunoprecipitated from the endoplasmic reticulum (ER) in
normal neurons. The N-terminal domain of PrPC binds to puri-
fied human LRP1 with nanomolar affinity, even in the presence of
1mM of the LRP-specific chaperone, (RAP) (Taylor and Hooper,
2007).
For infectious prion protein (designated PrPSc) to act as a
template and convert normal PrPC to its distinctive pathogenic
conformation, the two forms of PrP must interact closely.
Interestingly, the neuronal receptor, that rapidly endocytoses the
PrPC, is the LRP1. Parkyn et al. (2008) showed here that on sen-
sory neurons LRP1 is also the receptor that binds and rapidly
endocytoses smaller oligomeric forms of infectious prion fibrils,
and recombinant PrP fibrils. When PrPSc is endocytosed, PrPSc
fibrils are routed to lysosomes, rather than recycled to the cell sur-
face with PrPC. Thus, although LRP1 binds both forms of PrP,
it traffics them to different destinations within sensory neurons.
The binding to ligand cluster 4 should enable genetic modifi-
cation of PrP binding without disrupting other roles of LRP1
essential to neuronal viability and function, thereby enabling
in vivo analysis of the role of this interaction in controlling both
prion and LRP1 biology (Parkyn et al., 2008; Jen et al., 2010).
However, the most important function of LRP1 in neurons
is the major role in the transport and metabolism of choles-
terol associated with ApoE-containing lipoproteins. Cholesterol
is an essential component of neuronal membrane and myelin
sheaths, and is crucial for synaptic integrity and neuronal func-
tion (Pfrieger, 2003). Reduced synthesis and increased need for
cholesterol by neurons in adult brains require active choles-
terol transport to these cells to support synaptic functions and
repair (Bu, 2009). Addition of cholesterol to cultured neurons
strongly enhances the number and efficacy of synapses in a ApoE
dependent manner (Mauch et al., 2001).
Brain ApoE particles, produced primarily by astrocytes, deliver
cholesterol and other lipids to neurons via ApoE receptors
(ApoER), which belong to the low-density lipoprotein receptor
family (Herz and Bock, 2002; Bu, 2009). ApoE promotes the
neuronal uptake of cholesterol via LRP1.
In addition to transporting ligands to the cells, ApoE receptors
also mediate cellular signaling by binding a variety of extracel-
lular ligands and intracellular adaptor proteins (Herz and Chen,
2006). The best characterized signaling pathway is triggered by
Reelin and mediated by type 2 of ApoER. It is well described that
Reelin signaling is crucial for neuronal migration (Trommsdorff
et al., 1999), dendritic spine development (Niu et al., 2008) and
synaptic plasticity (Beffert et al., 2005).
The association of ApoE with AD is very well described in
the literature. To since 1990’s the ApoE was immunochemically
localized to the senile plaques, vascular amyloid, and neurofib-
rillary tangles of AD. The gene for ApoE is located on chro-
mosome 19q13.2, within the region previously associated with
late-onset familial AD. Analysis of ApoE alleles in Alzheimer dis-
ease and controls demonstrated that there was a highly significant
association of ApoE type 4 allele (APOE-epsilon 4) and late-onset
Frontiers in Physiology | Membrane Physiology and Biophysics July 2012 | Volume 3 | Article 269 | 4
Spuch et al. LRP-1 and LRP-2 in the neuron
familial Alzheimer disease. Although biochemical evidence sug-
gests that ApoE interferes with Reelin binding to ApoE receptors
(D’Arcangelo et al., 1999), the relationship between the two pro-
teins is still not clear. In neurons, ApoE isoforms differentially
affect several signaling cascades through ApoE receptors, includ-
ing increased phosphorylation of disabled 1 (Dab1), activation
of the extracellular signal-regulated kinase 1/2 (ERK1/2) path-
way and inhibition of the c-Jun N-terminal kinase 1/2 (JNK1/2)
pathway (Hoe et al., 2005). ApoE4, but not ApoE3, signifi-
cantly increases resting calcium, calcium response to NMDA and
neurotoxicity in a LRP1 dependent manner (Qiu et al., 2003).
Interestingly, ApoE3/lipoprotein affords greater protection from
apoptosis than ApoE4/lipoprotein via LRP1-mediated signaling
that involves activation of protein kinase Cδ (PKCδ) and inacti-
vation of glycogen synthase kinase-3β (GSK3β) (Hayashi et al.,
2007). The implication of LRP1 and its ligands in the patho-
genesis of AD is very well described (Vasquez-Higuera et al.,
2009).
Several evidences implicated LRP in the pathogenesis of AD.
Another interestingly option is the relationship between extra-
cellular matrix and the LRP signaling. Heparan sulphate proteo-
glycans (HSPGs) are abundant cell surface receptors that interact
with a variety of ligands through electrostatic interactions (Poon
and Gariepy, 2007). HSPGs found on the surface of almost all
mammalian cells are members of the glycosaminoglycan family
of polysaccharides and are involved in a large number of bio-
logical processes. In neurodegenerative diseases several HSPGs
co-localize with senile plaques and cerebral amyloid angiopathy
(van Horssen et al., 2003). Heparin and heparan sulphate are able
to modify the properties of growth factors activities (Spuch et al.,
2004, 2006), in fact theses proteoglycans are able to bind to Aβ
(Brunden et al., 1993) and attenuate neurotoxicity and inflam-
matory activity of Aβ, suggesting a potentially important role
for HSPG in cellular metabolism of Aβ (Bergamaschini et al.,
2002). In addition, LRP1 and HSPG are part of an immunopre-
cipitable complex at the cell surface to mediate lipid metabolism
(Wilsie and Orlando, 2003). Aβ may initially bind to the HSPG
sites on the surface of the complex and then may undergo
endocytosis via LRP1, in a process analogous to another LRP1
ligand Internalization of ApoE/lipoprotein particles is partially
dependent on the HSPG and LRP1 complex (Mahley and Ji,
1999), suggesting a cooperative function for these ApoE recep-
tors at the neuronal and astrocytes cell surface (Kanekiyo et al.,
2011).
Intracellular domain (ICD)
LRP-1 has also been shown to interact with scaffolding and sig-
naling proteins via its intracellular domain in a phosphorylation-
dependent manner and to function as a co-receptor partnering
with other cell surface or integral membrane proteins. LRP-1
is thus implicated in two major physiological processes: endo-
cytosis and regulation of signaling pathways, which are both
involved in diverse biological roles including lipid metabolism,
cell growth/differentiation processes, degradation of proteases,
and tissue invasion. The embryonic lethal phenotype obtained
after target disruption of the LRP-1 gene in the mouse highlights
the biological importance of this receptor and revealed a critical,
but yet undefined role in development. Tissue-specific gene dele-
tion studies also reveal an important contribution of LRP1 in
the central nervous system, in vascular remodeling (especially
brain vascular endothelium), foam cell biology, and also in the
molecular mechanisms of atherosclerosis.
As the case for numerous receptor andmembrane proteins, the
extracellular domain (ECD) of LRP1 can be cleaved by cell sur-
face proteases and subsequently released into extracellular space
or the circulation (plasma or CSF) (Zlokovic, 2011). This cleaved
form of LRP1 contains the α-chain of about 515 kDa and a frag-
ment of β-chain of about 55 kDa, demonstrating that the cleavage
occurs close to the plasmamembrane (May et al., 2003). Enzymes
that can mediated this cleavage include the neuronal BACE1 (von
Einem et al., 2010) and metalloproteinase (Selvais et al., 2011).
The physiological mean of LRP1 soluble form is not certain,
but since the soluble form can still bind most of the LRP1 lig-
ands and thereby reduce their endocytoses by cellular LRP1, the
soluble fragmentmay serve to quench extracellular ligand interac-
tion with cell or regulate their intracellular trafficking. Zlokovic’s
group has identified the LRP1 such as a major Aβ-binding pro-
tein in plasma. This soluble receptor may bind 70–90% of the
Aβ that circulates in peripheral blood and seems to function as
a peripheral sink for Alzheimer’s disease causing brain Aβ. Using
a mouse model of Alzheimer’s disease, the authors demonstrated
that boosting the capacity of the sink by administering a form of
soluble LRP1, reduces brain amyloid plaque load and improves
learning and memory. They extend these results by demonstrat-
ing that patients with AD have depressed plasma soluble LRP1
levels.
There is growing evidence that proteolytic degradation of
membrane spanning regulatory proteins is involved in a variety of
important trans-membrane signaling processes. This mechanism
of regulated intramembrane proteolysis (RIP) enables them to
respond to extracellular signals. γ-secretase may play a central role
in a signaling paradigm that has been termed RIP. RIP processing
is described in different receptors such as p75NTR, ErbB4, APP,
Notch and also LRP1 and LRP2, by allowing ICD to translocate to
the nucleus (Hass et al., 2009; Spuch and Navarro, 2010a,b; Spuch
and Carro, 2011; Groot and Vooijs, 2012). Alternatively, RIP may
turn off signaling events in which the transmembrane anchored
protein is responsible for signaling and cleavage terminates the
signal.
An extremely important point in regards to RIP, largely
ignored by most investigators, is that the fate of any ICD is
dependent on its N-terminus that dictates the stability of the
cleaved products. According to the N-end rule, only ICDs whose
N-terminus evades ubiquitination escape degradation, whereas
fragments beginning in other residues undergo rapid proteasomal
degradation (Tasaki and Kwon, 2007).
This potential mechanism in LRP1 regulation involves the
cleavage of the transmembrane domain of the LRP1 β-chain by
RIP. The released fragment (LRP1-ICD) of 12 kDa might thus
translocate to the nucleus where it can regulate the transcription
of target genes (Derocq et al., 2012). LRP1 following PKC activa-
tion and metalloproteinase-induced shedding of the (ECD), the
LRP1-ICD is released from the membrane by γ-secretase. This
cytoplasmic fragment may have functions in the cytoplasm or in
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the nucleus, including transcriptional regulation. Although the
LRP1-ICD functions are still unknown, recently, one potential
target of the LRP1-ICD has been identified. Lipopolysaccharide
(LPS) increases the proteolytic processing of the ectodomain
of LRP1, which results in the γ-secretase-dependent release of
the LRP1-ICD from the plasma membrane and its subsequent
translocation to the nucleus, where it interacts with and represses
the interferon-γ promoter (Zurhove et al., 2008).
The LRP1-ICD fragment contains numerous motifs that have
been implicated in numerous signaling pathways: Two NPXY
motifs, where the distal motif is contiguous with a YXXL motif,
and two dileucine motifs. The YXXL motif is presumably the
most important onemediating LRP1 endocytosis (Li et al., 2000).
However, both NPXY motifs can bind and interact with numer-
ous cytosolic proteins such as, DAB1, FE65, JIP1, PSD-95, ShcA
or CED-6/GULP (Berger et al., 2010; Boucher and Herz, 2011).
In vitro studies have shown that the LRP1-ICD can colocalize
with the histone acetyl transferase Tip60 in the nucleus (Kinoshita
et al., 2003), which in turn can regulate transcription upon APP
cleavage (Baek et al., 2002) suggesting that the LRP1-ICD might
be able to regulate the transcriptional activity of the APP-Tip60
complex, and thus have a more general function as a regulator of
transcription.
LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2 (LRP2)
LRP2, also called megalin, is one of the largest cell surface glyco-
proteins present in vertebrates, is a transmembrane protein with
a non-glycosytaledmolecular weigh of 517 kDa (Saito et al., 1994;
Chowdhary et al., 1995; Spuch andNavarro, 2010a,b). This recep-
tor is structurally very similar to LRP1. LRP2 is composed of a
large ECD consisting of four cysteine-rich complement-type lig-
and binding repeats, responsible for ligand binding (Table 1), that
binds to the chaperone RAP (receptor associated protein) for its
folding in the (ER) (Bu andMarzolo, 2000). The repeats are sepa-
rated from each other by β-propeller domains (Saito et al., 1994),
structured by repeats of YWTD flanked by EGF-likemodules, that
are generally important for the proper receptor folding in this
family of proteins (Culi et al., 2004; Lighthouse et al., 2010) as
well as for the dissociation of their ligands in the acidic endoso-
mal compartment (Jeon et al., 2001). In addition, LRP2 contains
one transmembrane domain that targets it to membrane domains
rich in cholesterol and glycosphingolipids (Marzolo et al., 2003)
and is also a substrate for the γ-secretase complex (Zou et al.,
2004). Among these are three NPXYmotifs that have been linked
to LDLR and LRP1 internalizationmediated by clathrin, recycling
from the endosomal compartment to the plasma membrane and
basolateral distribution (Donoso et al., 2009). However, the roles
of these motifs have not been clearly defined for LRP2 (Figure 2).
LRP2 expression in the brain
In the healthy brain, the expression of LRP-2 is classically pub-
lished in ependymal cells lining the ventricular wall, capillar-
ies and choroid plexus (Zheng et al., 1994; Chun et al., 1999;
Carro et al., 2005). The expression is principally restricted to
epithelial cells, specifically at the apical surface (Willnow, 1999).
Interestingly, despite the presence of some putative basolateral
sorting motifs in the cytoplasmic domain of LRP2, its apical
localization depends mainly on sorting information present in
this domain of the receptor because its addition to a reporter
protein that lacks sorting information drives trafficking of the
reporter to the apical surface of polarized epithelial cells (Marzolo
et al., 2003) However, during the last years several papers were
published describing the expression of LRP2 within peripheral
and central nervous system. The first evidences for LRP2 local-
ization in the central nervous system were described through
developmental studies. It is well known that genetic deficiency
of LRP-2 or inactivation of the lrp2 gene leads to holoprosen-
cephalic phenotype, characterized by abnormal development of
the forebrain, absence of olfactory apparatus and cranio-facial
malformations (Assemat et al., 2005). A novel mutation in lrp2
gene that causes an enlarged cortex, abnormalities in the dorsal
diencephalon further hypertrophy of the choroid plexus of the
third ventricle was also identified (Zarbalis et al., 2004).
Within the central nervous system, further ependyma of the
choroid plexus (Spuch and Navarro, 2010a,b), LRP-2 is widely
expressed on neurons (LaFerla et al., 1997) and astrocytes (Bento-
Abreu et al., 2008). In astrocytes this receptor is required for
albumin binding and internalization into astrocytes inducing
synthesis of neurotrophic factors by the neighbouring neurons
(Bento-Abreu et al., 2009). Other observations identified that
LRP-2 is present in retinal ganglion cells and in astrocytic
processes of young and adult rats. In these cells, LRP-2 inter-
acted with metallothionein-IIA allowing the activation of differ-
ent intracellular signaling pathways involved in neuroprotection
(Fitzgerald et al., 2007). In this context, studying the role of met-
allothionein as a neuroprotective factor and ligand of LRP-2, it
was described the expression of LRP-2 in cerebellar granule cells
being mediator of the neuroprotective action of metallothionein
(Ambjorn et al., 2008). Due to the growing evidence that LRP-2
expression in the brain is not restricted to tight-junction epithe-
lia, oligodendrocytes and glial cells, our group recently published
the broad expression of this endocytic receptor in different neu-
ronal populations of the brain. In brain samples from healthy
humans, monkeys, pigs, mice and rats we demonstrated LRP2
localization in different neuronal populations from cerebral cor-
tex, hippocampus, striatum, thalamus, olfactory bulb and cere-
bellum (Alvira-Botero et al., 2010). Interestingly, in brain tissues
from patients diagnosed with Alzheimer’s disease, LRP-2 expres-
sion has been immunohistochemically detected in neurons, even
being up regulated in damaged neurons (LaFerla et al., 1997).
LRP2 and signal transduction in the brain
LRP2 is an endocytic receptor which binds its extracellular ligands
before an endocytic uptake. The activation of different signaling
pathways is due to LRP2 dependent internalization of a num-
ber of ligands representing a wide variety of molecules, includ-
ing lipoproteins, hormones, vitamin-binding proteins and drugs
(Table 1). The signaling functions in the cytoplasm are controlled
by their interaction with adaptor proteins that recognize specific
motifs within the cytoplasmic domains of LRP-2. There are evi-
dences linking LRP2 endocytosis to non-clathrin mediated path-
ways involving trafficking proteins such as the small GTPase Arf6
(Wolff et al., 2008) and caveolin 1 (Bento-Abreu et al., 2009). Two
cytoplasmic proline-rich sequences and a PDZ-binding motif
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FIGURE 2 | LRP2 is structurally similar to LRP1. The ECD of LRP2 contains
four clusters (1–4) of lipoprotein receptor ligand-binding repeats, growth
factor repeats, an EGF repeat, and YWTD spacer regions. Interestingly, the
second cluster has been identified as a common binding site for several
ligands including Apo E, Apo M, retinol binding protein and transthyretin. The
fourth cluster has been identified as binding site for Aβ. The LRP2 is also
proteolytically cleaved to generate two subunits: (A) the N-terminal (soluble
LRP2) containing the ligand-binding domains and (B) the C-terminal subunit
containing an extracellular fragment (CTF), the transmembrane spanning
domain and the ICD. The ICD contains diverse potential endocytosis and
signaling motifs. The ICD binds adaptor proteins important for LRP2-mediated
endocytoses, such as Dab2 and is able to induce intracellular events such as
RIP signaling. The cytoplasmic domain of LRP2 has several putative
internalization motifs, including one dileucine and three NPxY motifs. In
addition, it contains two proline-rich sequences, one PDZ terminal motif,
several putative protein kinase C and casein kinase II phosphorylation
motifs as well as one protein kinase A phosphorylation motif.
Under basal conditions, these motifs contribute little to the
phosphorylation of the LRP2 cytoplasmic domain. Although there are
few evidences about the cytoplasmic regulation of LRP1 and LRP2, the
mechanism is conserved in the gene evolution and probably the
regulation and trafficking of both receptors in neurons are very similar. With
arrows is indicating the cleavage events in the molecule and the resulting
fragments.
have been implicated in the direct and indirect interaction of
LRP2 with cytoskeletal and cytosolic scaffold and signaling pro-
teins, such as GIPC/ synectin, megalin-binding protein, ANKRA,
myosin VI, SKIP, Disabled 2 (Dab2) and APPL1 (Rader et al.,
2000; Patrie et al., 2001; Larsson et al., 2003; Spuch and Navarro,
2010a,b). An interesting feature of LRP2 is that it is constitu-
tively phosphorylated by GSK3 at a PPPSP motif, contained in
a distal proline-rich motif of the cytoplasmic tail. This PPPSP
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motif is the most significant in terms of basal phosphorylation
of the receptor, despite the presence of several other consensus
phosphorylation sites for PKC, CK-II and PKA and its function
is related to the control of LRP2 recycling from the endosomes
(Yuseff et al., 2007).
Recent data identify a critical role for LRP2 in SHH signal-
ing and reveal the molecular mechanism underlying forebrain
anomalies in mice and patients with Lrp2 defects. This group
identified LRP2 as a component of the SHH signaling machin-
ery in the rostral diencephalon ventral midline. LRP2 is acting
as an apical SHH-binding protein that sequesters SHH in its tar-
get field and controls internalization and cellular trafficking of
SHH/patched 1 complexes (Christ et al., 2012).
In the brain, LRP2 participates in endocytosis and internal-
ization of ApoE, APP and Aβ peptide (LaFerla et al., 1997).
The first signaling event described for LRP2 was suggested by
Strickland’s group showing that LRP2 is responsible for soluble-
APP endocytosis (Kounnas et al., 2008). Recently, our group
published in cortical and hippocampal neurons that LRP2 is able
to form a macromolecular complex together with APP and Fe65
acting as a negative regulator of neurite branching and as medi-
ator of Aβ neurotoxicity (Alvira-Botero et al., 2010). In another
study with granule cells from cerebellum described as metal-
lothionein induced neuronal differentiation, survival and initiate
signal transduction pathways resulting in neurite outgrowth by
binding of LRP2 (Ambjorn et al., 2008). In spite of the poor infor-
mation available it seems that the activation of LRP2 upon ligand
binding mediates neurite outgrowth and apoptosis.
Also, it was demonstrated that LRP2, a receptor implicated
in BMP4 clearance is specifically expressed in ependymal cells
of the lateral ventricles in the adult brain. Intriguingly, expres-
sion is restricted to the ependyma that faces the stem cell niche.
Expression is not seen in ependyma elsewhere in the lateral ven-
tricles or in the dentate gyrus, the second major neurogenic
zone of the adult brain. This group further showed that lack of
LRP2 expression in adult mice results in impaired proliferation
of neural precursor cells in the subependymal zone resulting in
decreased numbers of neuroblasts reaching the olfactory bulb.
Reduced neurogenesis coincides with increased BMP4 expression
and enhanced activation of downstream mediators phospho-
SMAD1/5/8 and ID3 in the stem cell niche. These findings sug-
gest a novel mechanism whereby LRP2-mediated catabolism of
BMP4 in the ependyma modulates the microenvironment of the
subependymal zone and enables adult neurogenesis to proceed
(Gajera et al., 2010).
Intracellular domain
Similarly to what described for LRP1, LRP2 is also able to ini-
tiate signaling events related with RIP processing in a manner
similar to that described for APP and Notch. This receptor under-
goes proteolytic shedding of the ECD by a metalloproteinase.
It has recently been shown that the cytoplasmic tail of LRP-2
can be processed intramembranously by a γ-secretase activity
that releases its ICD-LRP2 (Biemesderfer, 2006). Following the
RIP processing in the cytoplasmic domain of LRP2, this receptor
also undergoes proteolytic shedding of the ECD by a metallopro-
teinase, generating truncated forms, also named soluble-LRP2,
corresponding with the 4-loop of LRP-2 (Ishida et al., 2006). The
COOH-terminal fragment is in turn released from themembrane
by γ-secretase activity acting at a cleavage site within the proteins
membrane spanning domain.Once released, the COOH-terminal
domain traffics to the nucleus where, through interaction with
transcription factors, it controls expression of target genes (Ebinu
and Yankner, 2002). However, related to COOH fragment of
LRP-2 nothing is known about its regulation in neurons. Our
group found LRP2-ICD in rat hippocampal neurons in vitro
(unpublished data). Furthermore, the function of these events
in the context of the brain is completely unknown. We suggest
that LRP2-ICD could be regulated by LRP2 ligands and may be
involved in gene transcriptions and apoptosis events, although
more investigations are necessary to discover relevant facts about
LRP2-ICD in neurons. The unique evidence about the function
of LRP2-ICD was described in kidney, where it seems likely that
RIP of LRP-2 is part of a more complex molecular pathway that
ensures LRP2 expression at some necessary physiologic level (Li
et al., 2008).
LRP-1/LRP-2 ROLES IN AD
Advancing age is a major risk factor for many neurodegenerative
disorders, and the major risk factor for AD, a disease charac-
terized by progressive memory and cognitive loss (Selkoe et al.,
2012). The most accepted hypothesis for the mechanism of brain
injury in AD is the "amyloid cascade," comprising amyloid accu-
mulation in the brain, the formation of toxic oligomeric and
intermediate forms of Aβ peptides, amyloid plaques, inflamma-
tion and the induction of neurofibrillary tangles (Jin et al., 2011).
There is accumulation of Aβ in both, the normal aging brain and
the AD brain, thought to be related to defective Aβ clearance
rather than increased Aβ production (Zlokovic et al., 2010). This
has recently been shown to be the case in AD. Clearance of this
peptide from the brain occurs via active transport at the inter-
faces separating the central nervous system from the peripheral
circulation. Through the BBB and the BCSFB, LRP1 and LRP2,
facilitate the clearance of the Aβ peptide that is produced by amy-
loidogenic processing of the APP, which can form complexes with
different LRPs ligands such as ApoJ (also called clusterin) and
ApoE (Zlokovic, 2004, 2011; Nuutinen et al., 2009) and ApoE.
In addition to these ligands, a neuroprotective role for the Aβ-
binding protein called gelsolin (Carro, 2010), that is produced
and secreted in the epithelial cells of the choroid plexus (Vargas
et al., 2010a), was recently demonstrated. Gelsolin has neuropro-
tective functions in controlling the Aβ-induced production of NO
and apoptosis as well as cytoskeletal disruptions in the epithelial
cells of the cerebrospinal fluid barrier (Vargas et al., 2010a).
Several lines of evidence have implicated LRP and LRP lig-
ands in the pathogenesis of Alzheimer’s disease (Nieoullon, 2011).
First, LRP is a major neuronal receptor for ApoE/lipoprotein, and
the epsilllon4 allele of ApoE is a strong genetic risk factor for late-
onset AD. LRP-mediated brain metabolism of ApoE/lipoprotein
can also influence the metabolism of cholesterol, which has been
suggested to contribute to the pathogenesis of AD by regulat-
ing Aβ metabolism. Second, immunoreactive staining of sev-
eral LRP ligands (e.g., ApoE, α2M, and tissue factor pathway
inhibitor) as well as LRP itself has been detected in senile plaques.
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Third, some genetics studies have suggested that LRP1 and LRP2
are linked to AD and cerebral amyloid angiopathy (Ballatore et al.,
2007). Two recent genome-wide association studies have reported
that PICALM (phosphatidylinositol binding clathrin assembly
protein) and ApoJ (also known as clusterin) are the only two AD
susceptibility genes (Harold et al., 2009). However, this year it was
published a study where the 10 most promising late-onset AD
susceptibility genes identified through several recent large GWAS
(APOE, CLU, PICALM, CR1, BIN1, ABCA7, MS4A6A, CD33,
CD2AP, and EPHA1). This study has been identified curiously,
apart from the APOE locus which showed compelling evidence of
association with risk on human life span, none of the other gene
loci demonstrated significant evidence of association (Shi et al.,
2012). However, last studies of Carro’s group demonstrated three
new polymorphisms in the genes PLA2G3, IGF-I and LRP2 asso-
ciated with AD in a Spanish population (Martínez-García et al.,
2010; Vargas et al., 2010b, 2011).
Together these observations indicate that LRP can participate
in AD pathogenesis by altering the catabolism of LRP ligands
(e.g., IGF-I, ApoE/lipoprotein/cholesterol, tPA, and α2M) and/or
influencing Aβmetabolism and accumulation (Carro et al., 2002,
2005, 2006). Further, it has been shown that the LRP1 and LRP2
cytoplasmic C-terminal domain interact with APP cytoplasmic
domain via FE65, which in turn influences APP processing and
Aβ generation (Pietrzik et al., 2004; Alvira-Botero et al., 2010).
Recent findings have revealed the roles of γ-secretase and LRP1
in the inhibition of the inflammatory response suggesting that
both proteins may serve as potential therapeutic targets for the
modulation of inflammation (Zurhove et al., 2008). Furthermore,
none is known about the speculative effect of LRP2 in the
neuroinflammation. Probably, the modulation of LRP1 and LRP2
in the different cells of the neurovascular unit could be new
therapeutic strategy.
CONCLUSIONS
In summary, we have reviewed recent evidence suggesting that
LRP1 and LRP2 have amajor role in regulating brain and systemic
clearance of Aβ. Since the discovery of both LRPs as important
endocytic receptors present in the brain endothelium and epithe-
lial cells of the choroid plexus several new ligands and functions
for these proteins have been uncovered. Recent findings in LRPs
functions in the brain cells (astrocytes, glial cells and neurons)
and their role in the internalization of different molecules, open
the possibility that these receptors can be used as a target and reg-
ulator of signal transduction pathways, as well as the emergence of
its roles in neurodegeneration and regeneration processes and in
chronic and genetic diseases. The modulation of LRP1 and LRP2
in the different cells of the neurovascular unit could be new strat-
egy therapeutic. However, as a note of caution, the development
of LRPs-based therapies for neurodegenerative diseases requires
careful toxicity and safety monitoring of unwanted potential side
effects given that LRPs participate in multiple control systems in
the body (cellular transport in different organs, anticoagulation
process and inflammation).
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